Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors

Cancer Epidemiology

Volumn 37, Issue 2, 2013, Pages 191-196

  Dreyfus, Brian ^a   Kawabata, Hugh ^a   Gomez, Andres ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Adverse effects; Drug toxicity; Gastrointestinal neoplasm; Kidney neoplasm; Liver neoplasm; Neoplasm

Indexed keywords

BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BRAIN DISEASE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DYSPHONIA; ERYTHEMA MULTIFORME; FEMALE; HEALTH INSURANCE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; ICD-9-CM; INCIDENCE; KIDNEY CANCER; KIDNEY FAILURE; LIVER CANCER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTIC SYNDROME; PANCREATITIS; PRESCRIPTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; STOMATITIS; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; VOMITING; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STEVENS-JOHNSON SYNDROME; SURVIVAL RATE; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VOMITING; YOUNG ADULT;

EID: 84875859385     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.11.001     Document Type: Article

References (27)

1. AstraZeneca. Vandetanib - prescribing information. Available from URL: [accessed 10.06.11]. http://www1.astrazeneca-us.com/pi/vandetanib.pdf.
2. Bayer. Nexavar - prescribing information. Available from URL: [accessed 10.06.11]. http://www.nexavar.com/scripts/pages/en/index.php.
3. Genentech. Avastin - prescribing information. Available from URL: [accessed 10.06.11]. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pd f.
4. GSK. Votrient - prescribing information. Available from URL: [accessed 10.06.11]. https://www.gsksource.com/gskprm/en/US/adirect/gskprm%3Fcmd=ProductDetai lPage%26product_id=1279563278373%26featureKey=601903.
5. Pfizer. Sutent - prescribing information. Available from URL: [accessed 10.06.11]. http://www.sutent.com/.
6. American Cancer Society Cancer facts & figures 2010 2010, Available from URL: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/can cer-facts-and-figures-2010.
7. Cooper G.S., Yuan Z., Stange K.C., Dennis L.K., Amini S.B., Rimm A.A. The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care 1999, 37(5):436-444.
8. Eide M.J., Krajenta R., Johnson D., Long J.J., Jacobsen G., Asgari M.M., et al. Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol 2010, 171(1):123-128.
9. Ramsey S.D., Scoggins J.F., Blough D.K., McDermott C.L., Reyes C.M. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm 2009, 15(8):659-668.
10. Rolnick S.J., Hart G., Barton M.B., Herrinton L., Flores S.K., Paulsen K.J., et al. Comparing breast cancer case identification using HMO computerized diagnostic data and SEER data. Am J Manage Care 2004, 10(4):257-262.
11. Liang S.Y., Phillips K.A., Wang G., Keohane C., Armstrong J., Morris W.M., et al. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care 2011, 49(6):e1-e8.
12. Birman-Deych E., Waterman A.D., Yan Y., Nilasena D.S., Radford M.J., Gage B.F. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005, 43(5):480-485.
13. Myers R.P., Leung Y., Shaheen A.A., Li B. Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data. BMC Health Serv Res 2007, 7:159.
14. White R.H., Garcia M., Sadeghi B., Tancredi D.J., Zrelak P., Cuny J., et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 2010, 126(1):61-67.
15. Waikar S.S., Wald R., Chertow G.M., Curhan G.C., Winkelmayer W.C., Liangos O., et al. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006, 17(6):1688-1694.
16. Winkelmayer W.C., Schneeweiss S., Mogun H., Patrick A.R., Avorn J., Solomon D.H. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis 2005, 46(2):225-232.
17. Navaneethan S.D., Jolly S.E., Schold J.D., Arrigain S., Saupe W., Sharp J., et al. Development and validation of an electronic health record-based chronic kidney disease registry. Clin J Am Soc Nephrol 2011, 6(1):40-49.
18. Varas-Lorenzo C., Castellsague J., Stang M.R., Tomas L., Aguado J., Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf 2008, 17(8):842-852.
19. Andrade S.E., Gurwitz J.H., Chan K.A., Donahue J.G., Beck A., Boles M., et al. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol 2002, 55(3):310-313.
20. Arnason T., Wells P.S., van Walraven C., Forster A.J. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006, 118(2):253-262.
21. Abraham N.S., Cohen D.C., Rivers B., Richardson P. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther 2006, 24(2):299-306.
22. Cattaruzzi C., Troncon M.G., Agostinis L., Garcia Rodriguez L.A. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol 1999, 52(6):499-502.
23. Raiford D.S., Perez Gutthann S., Garcia Rodriguez L.A. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996, 7(1):101-104.
24. Wahl P.M., Rodgers K., Schneeweiss S., Gage B.F., Butler J., Wilmer C., et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010, 19(6):596-603.
25. Curtis L.H., Hammill B.G., Schulman K.A., Cousins S.W. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010, 128(10):1273-1279.
26. Happe L.E., Rao S.V., Horblyuk R., Franklin M., Lunacsek O.E., Menditto L. Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. Curr Med Res Opin 2009, 25(2):413-420.
27. Rothman K.J., Boice J.D. Epidemiologic analysis with a programmable calculator. NIH 1979, 79-1649:31-32.